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In the first quarter of 2012, publicly traded companies in the cell-based therapy industry continued to show
promising overall growth. Highlights included $85 million in new capital investment and steady clinical trial
progress.Almost 50 years on from McCulloch and
Till’s pioneering work into ‘‘spleen colony
forming cells,’’ much has changed in
the stem cell field (Becker et al., 1963,
Siminovitch et al., 1963). From a state of
relative obscurity, stem cell research has
emerged as one of the most high-profile
and promising areas of 21st century
science, attracting an unprecedented
mixture of passionate public support,
and in some cases, fierce opposition
(Blendon et al., 2011). Today, the transla-
tion of basic stem cell science into thera-
peutically and commercially meaningful
outcomes is at the core of the emerging
cell therapy industry. This new global
industry is at an exciting crossroads:
from a principally scientific discipline, a
strong translational effort is now emerg-
ing, and with it, the prospect of a distinct
healthcare sector based on living cells
as therapies (Mason et al., 2011).
Therefore, we are delighted to launch
the ‘‘Industry Progress’’ series in Cell
Stem Cell. This quarterly feature aims
to provide a timely summary of the per-
formance of publicly traded companies
operating in the cell-based therapy sector
in the previous quarter together with
a brief summary of news regarding key
developments for those businesses. The
majority of these companies are devel-
oping products based on stem and/or
progenitor cells. This feature is supported
by an expert advisory committee (Table 1)
formed from leading representatives of492 Cell Stem Cell 10, May 4, 2012 ª2012 Elmajor stakeholder communities including
academics, scientists, clinicians, lawyers,
public funding agencies, and venture
capitalists. The articles will be aligned
with the financial calendar, and will report
events that may impact the commercial
development of a sustainable cell-based
therapy industry. Such events will include
updates relating to clinical trial progress,
intellectual property, breakthroughs in
translational science, and current senti-
ment in the life science investor commu-
nity. The overall intention is to provide
information (based on publicly available
data) that will help the broader readership
of Cell Stem Cell track the translation of
cutting-edge science into therapies. A
complementary ambition is that this
resource will raise the profile of the
industry among vital partners such as
Big Pharma, as well as wider potential
sources of translational funding and stra-
tegic partnerships (McKernan et al.,
2010, Rao, 2011).
Company News Q1 2012: January 1
to March 31, 2012
Aastrom Biosciences (Ann Harbor, MI,
USA) commenced patient enrollment in
a phase III clinical trial of ixmyelocel-T
(autologous expanded multicellular
mixture of bone-marrow-derived mesen-
chymal and monocytic stem and progen-
itor cells, activated macrophages, and
hematopoietic cells) to treat critical limb
ischemia. The trial aims to treat 594sevier Inc.patients across 79 US sites. The company
released preliminary preclinical data ad-
dressing potential mechanisms of action
of ixmyelocel-T. Aastrom also completed
a private investment whose net of fees
raised approximately $38M (see Table 2).
Advanced Cell Technology (ACT)
(Marlborough, MA, USA) completed
treatment of the first patient cohort in its
phase I/II trial for Stargardt’s macular
dystrophy using retinal pigment epithelial
cells derived from human embryonic
stem cells, with approval to begin dosing
its next cohort expected in spring 2012.
This follows the publication of preliminary
results for one SMD patient and one dry
AMD patient. ACT also announced the
institutional review board approval of
Wills Eye Institute (Philadelphia PA, USA)
as a clinical trial site. Increased clinical
trial activity contributed to a rise in opera-
tional expenditure from $8.8M in 2010 to
$13.6M in 2011.
Athersys (Cleveland, OH, USA) was
awarded a SBIR Fast-Track grant of up
to $1.9M from the National Institute of
Neurological Disorders and Stroke to
develop its multipotent adult progeni-
tor cell product, MultiStem, for the
treatment of traumatic brain injury in
collaboration with the University of
Texas Medical School (Houston, TX,
USA). In addition, Athersys’ subsidiary,
ReGenesys (Heverlee, Belgium), was
awarded a $1.2M grant from Belgium’s
Agency for Innovation by Science and
Table 1. Industry Progress Advisory Committee
Name Primary Affiliation
Bruce Booth Atlas Venture
George Daley Harvard University
Alex Denoon Lawford Davies Denoon
Guillermo Garcia-Cardena Harvard University
Carl June University of Pennsylvania
James Lawford Davies Lawford Davies Denoon
Bruce Levine University of Pennsylvania
Roger Pedersen University of Cambridge
Evan Snyder Sanford-Burnham Medical Research Institute
Alan Trounson California Institute for Regenerative Medicine
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formulation and manufacturing capabil-
ities in collaboration with the Katholieke
Universiteit of Leuven (Belgium).
BioSante Pharmaceuticals (Lincolnshire,
IL, USA) reported results from a phase
Ib clinical trial, including an increase in
the median survival of pancreatic cancer
patients with previously treated, locally
advanced, or metastatic pancreatic
adenocarcinoma, from 3.3 months when
treated with ipilimumab to 5.5 months on
the combination of ipilimumab plus
GVAX (allogeneic pancreatic tumor cells
transfected with a GM-CSF gene). The
company plans to commence a multi-
center study later in 2012. BioSante also
announced a small increase in net losses
of 2011 of $51.6M compared to $46.2M
in 2010, citing costs associated with theTable 2. Summary of Major Financial Investm
Q1 2012
Company Name
Major Financial
in Company (mi
Aastrom Biosciences $40.0
$1.9
$1.2
Cytomedix $5.0
Intellicell Biosciences $0.25
$0.25
International Stem Cell $5.0
InVivo Therapeutics $17.4
$2.6
Neuralstem $5.2
Pluristem Therapeutics $2.4
Sernova $3.5
Total $84.7
Only completed financings are included in this tab
included in future articles.
aOnly lists amounts >$0.25M.clinical development of LibiGel, a gel
formulation of testosterone—a product
that failed to meet its coprimary or
secondary endpoints in a phase III clinical
trial.
BioTime (Alameda, CA, USA) an-
nounced the successful negotiation of
an exclusive license from the Wistar Insti-
tute (Philadelphia, PA, USA) for tech-
nology related to the SP100 gene, a key
regulatory gene underlying stem cell re-
programming. BioTime has also agreed
to fund continued research into the thera-
peutic potential of the gene at the Wistar
Institute in return for the right to license
technologies resulting from the research.
The company announced an increase in
total revenue for 2011 to $4.4M, up from
$3.7M in 2010. However, total expenses
for 2011 increased to $23M comparedents in Public Cell Therapy Companies in
Investments
llions)a Type of Transaction
private investment
grant (NINDS)
grant (IWT)
private investment
private investment
private investment
private investment
public stock offering
private investment
private investment
grant (Israeli Govt.)
private investment
—
le. The closure of any outstanding offers will be
Cell Stem Ceto $13.5M in 2010, which the company
attributes to several factors, including
increased R&D expenditure and a number
of acquisitions.
Brainstorm Cell Therapy (New York, NY,
USA) announced plans to initiate a pre-
clinical study in Q2 2012 assessing the
efficacy of its differentiated MSC product,
NurOwn, for multiple sclerosis patients.
The company also announced promising
preclinical data suggesting some thera-
peutic benefit of its NurOwn technology
in animal models of Huntington’s disease.
Cryo-Cell International (Oldsmar, FL,
USA) announced an agreement with
Stanford University (Stanford, CA, USA)
to investigate the efficacy of MSC-like
cells derived from menstrual blood in
a model of pancreatic islet transplanta-
tion for type 1 diabetes. Additionally, the
company announced positive results of
a study of amyotrophic lateral sclerosis
(ALS) in mice by repeated, low-dose
injections of mononuclear cells derived
from human umbilical cord blood.
Cytomedix (Gaithersburg, MD, USA)
completed the acquisition of Aldagen,
Inc. (Durham, NC, USA), a privately held
biopharmaceutical company developing
cell therapies based on its proprietary
ALDH bright cell technology. In addition,
Aldagen investors purchased $5M of
Cytomedix stock in a private investment
concurrent with the closing of the acqui-
sition. The company also announced
total product sales of $5.9M in 2011,
compared with $3.8M in 2010, attributed
in part to increased sales of its Angel
whole blood separation system for the
production of autologous platelet-rich
plasma.
Cytori (San Diego, CA, USA) received
FDA Investigational Device Exemption
approval to commence a multicenter
trial of its Celution System to prepare
adipose-derived stem cells (ADRCs) to
treat chronic myocardial ischemia. The
company also received FDA 510(k) clear-
ance for its Puregraft 850 System for body
contouring using the patient’s own fat.
This new device produces larger tissue
volumes compared to previous genera-
tion devices, which the company hopes
will expand the range of soft tissue pro-
cedures in which the product platform
can be applied. These events comple-
ment the recent publication of results
from RESTORE-2, a prospective clinical
trial using ADRC-enriched fat graftingll 10, May 4, 2012 ª2012 Elsevier Inc. 493
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surgery.
Dendreon (Seattle, WA, USA) an-
nounced that Mitchell H. Gold, who has
acted as President and Chief Executive
Officer for more than a decade, will be
succeeded by John H. Johnson. The
company reported improved financial
results, with product revenue for 2011 of
$213.5M compared with $48M for 2010,
leading to a net loss in 2011 of $337.8M
compared with $439.5M in 2010.
ImmunoCellular (Woodland Hills, CA,
USA) announced the allowance of US
patent claims related to the company’s
method of treating glioblastoma multi-
forme (GBM) in a patient by targeting
cancer stem cells. The company’s patent,
‘‘Cancer Stem Cell Antigen Vaccines
and Methods,’’ covers various methods
of using dendritic cells combined with
antigens derived from glioblastoma cells
for the treatment of GBM. ImmunoCellular
also holds an exclusive worldwide
licensing agreement with the University
of Pennsylvania (PA, USA) for a patent-
pending technology for the production of
high-activity dendritic cells. In a similar
agreement, the company announced
a worldwide license with The Johns
Hopkins University (Baltimore, MD, USA)
concerning intellectual property sur-
rounding the tumor-associated antigen
mesothelin, which it aims to exploit in
relation to its candidate, ICT-140, a
multivalent, dendritic-cell-based vaccine
for the treatment of ovarian cancer.
The company also made a positive an-
nouncement regarding the consistency
of its proprietary manufacturing tech-
nique for its dendritic cell vaccine, ICT-
107, for the treatment of GBM.
International Stem Cell (Carlsbad, CA,
USA) announced the successful raising
of $5M through a private investment.
The company also announced revenues
of $4.5M for 2011, an increase of 189%
from 2010.
InVivo Therapeutics (Cambridge, MA,
USA) issued a public offering to the
value of $17.4M, which is expected to
generate net proceeds of approximately
$15.7M. This is supplemented by a direct
raising of $2.6M, thus increasing InVivo’s
total capital raised this quarter to $20M
gross of fees.
Intellicell Biosciences (New York, NY,
USA) undertook a number of private
investments to raise capital in excess of494 Cell Stem Cell 10, May 4, 2012 ª2012 El$2.5M. The company also received
a warning letter from the FDA questioning
several points relating to its ADRCs,
including the category of regulation,
concerns regarding ‘‘off-label’’ marketing,
and Good Manufacturing Practice (GMP)
deficiencies. The company stated that it
intends to address the issues raised by,
for example, moving into a new GMP
facility in April 2012.
Islet Sciences (New York, NY, USA)
entered into an agreement to acquire
DiaKine Therapeutics, Inc. (Norfolk, VA,
USA), a biopharmaceutical company
developing proprietary drugs for unmet
medical needs in diabetes and com-
plications related to diabetes.
Mesoblast (Melbourne, Australia)
received FDA clearance to commence
phase II clinical trials for its mesenchymal
precursor cell therapy to treat type 2
diabetes. In addition the company re-
ported cash reserves of $241M as of
December 31, 2011.
NeoStem (New York, NY, USA)
company Amorcyte (Allendale, NJ, USA)
announced the enrollment of the first
patient in their PreSERVE phase II trial of
AMR-001, an autologous bone-marrow-
derived cell therapy for acute myocar-
dial infarction. In addition, NeoStem’s
manufacturing subsidiary Progenitor Cell
Therapy (Allendale, NJ, USA) has entered
into an agreement to provide contract
manufacturing and regulatory services
related to the development of Islet
Sciences (New York, NY, USA) PTM,
an injectable suspension of microencap-
sulated, insulin-producing,pancreatic islet
cells harvested from pathogen-free pigs.
Neuralstem (Rockville, MD, USA)
announced the completion of a direct
sale of common stock generating gross
proceeds of $5.2M. Additionally, the
company reported positive preliminary
results in a safety study into the lumbar
intraspinal injection of neural stem cells
in patients with amyotrophic lateral scle-
rosis (ALS). Neuralstem has received
FDA approval to commence a trial in
ALS patients with the goal of protecting
the motor neurons associated with respi-
ratory function.
Opexa Therapeutics (The Woodlands,
TX, USA) executed an agreement with
Pharmaceutical Research Associates
Inc. (Raleigh, NC, USA) to provide
contract research organization services
to support Opexa’s upcoming phase IIbsevier Inc.clinical trials for Tovaxin, a T cell therapy
for multiple sclerosis.
Osiris Therapeutics (Columbia, MD,
USA) continues to develop Prochymal to
treat graft versus host disease, despite
the recent termination of a commer-
cialization agreement with Genzyme
(Cambridge, MA, USA), a Sanofi (Paris,
France) company. The circumstances of
the termination suggest that all rights
to Prochymal revert back to Osiris
without compensation to Sanofi, and
that Osiris is free to commercialize or
enter into commercialization agreements
for Prochymal with other parties without
restriction.
Pluristem Therapeutics (Haifa, Israel)
was awarded a $2.4M grant by the Israeli
government in January. The grant will be
used to cover R&D expenses. Further-
more, the company has initiated a scale-
up program intended to treble the pro-
ductivity of its current manufacturing
bioreactors, aiming to yield 100 doses of
300M Placental eXpanded (PLX) cells
per reactor run. PLXs are currently in clin-
ical trials for critical limb ischemia, and
promising recent data in animal models
also suggest potential in acutemyocardial
infarction.
Sernova (London, ON, Canada) raised
$3.5M gross proceeds through a private
investment. The funds will be used by
Sernova for research and development of
its proprietary Cell Pouch System, and to
finance its upcoming first-in-man clinical
trial to be conducted at the University of
Alberta (Canada) by Dr. James Shapiro.
StemCells (Newark, NJ, USA) an-
nounced FDA authorization to commence
a phase I/II clinical trial of HuCNS-SC,
purified human neural stem cells, for the
treatment of dry age-related macular
degeneration. The company also had
positive results from a phase I trial of
HuCNS-SC in Pelizaeus-Merzbacher
disease, in which safety was demon-
strated in all four trial patients and
improved motor and/or cognitive function
in three of the four patients. StemCells has
granted genOway a worldwide, exclusive
license to its Internal Ribosome Entry
Site technology for use in the develop-
ment and commercialization of geneti-
cally engineered mice.
Tengion (Winston-Salem, NC, USA)
submitted a pre-Investigational New Drug
application to the FDA for its lead pre-
clinical program, Neo-Kidney Augment.
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Figure 1. The Change in Stock Price of Individual, publicly Traded Cell Therapy Companies from January 1 to March 31, 2012
White bars represent an overall increase in stock price and red bars represent an overall decrease. Vertical lines correspond to the maximum andminimum share
prices attained throughout the quarter. Values in brackets next to company names represent the market capitalization of the company (in millions of dollars). The
company order is alphabetized as per their stock ticker symbols. See also Table S1.
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delay the need for dialysis or kidney
transplant by catalyzing the regeneration
of functional kidney tissue in patients
with advanced chronic renal disease. The
company also reported that a fourth
patient was implanted with the Neo-
Urinary Conduit in ongoing clinical trials
of the company’s lead tissue-engineered
construct.
TiGenix (Leuven, Belgium) reported
positive results from a compassionate
use program for its EMA-approved
product ChrondroCelect. The 4 year
study involved 370 patients distributed
across 43 orthopedic centers in seven
European countries. The results of the
new study reinforced proof of efficacy
data from the earlier 2009 clinical trial
(43 patients).
Index and Stock Performance
The Cell Therapy Industry Index (see
Table S1 available online) is an equally
weighted index that tracks the perfor-
mance of stocks in major publicly traded
companies operating in the cell-based
therapy arena. The change in the share
price for the individual companies during
Q1 2012 is shown in Figure 1.
In the first quarter of 2012, the index
as a whole performed well in compar-ison to other benchmarks, exceeding
returns from both the S&P 500 (com-
posed of major companies from all
sectors) and the AMEX Pharmaceutical,
which currently includes sixteen major
Big Pharma companies. The overall
value of the Cell Therapy Industry Index
increased 13.5% relative to the fourth
quarter of 2011. The NASDAQ com-
posite, consisting of high-tech high-
growth companies of a range of sizes,
produced the greatest returns. The
performance of the NASDAQ Biotech-
nology index mirrors that of the broader
NASDAQ index, and is potentially the
most meaningful benchmark to use as
comparison for the Cell Therapy
Industry Index. In this quarter, the Cell
Therapy Industry Index underperformed
the NASDAQ Biotechnology Index by
5%, but in light of the ongoing volatility
(Brindley et al., 2011) this is potentially
unlikely to have a major impact on the
long-term positive outlook. This inter-
pretation is consistent with other recent
academic publications relating to prog-
ress in the tissue engineering and
stem cell industry (Jaklenac et al.,
2012).
One company with a notable change
during this past quarter is Islet
Sciences, whose significant stock priceCell Stem Ceincrease of 142% represented the
greatest rise of any one company in
the index. This increase may reflect the
acquisition of DiaKine Therapeutics
Inc., and the corresponding promising
pipeline of potential diabetes therapies.
Also of interest this quarter is the overall
Q1 performance of Osiris Therapeutics,
which, despite the high-profile termina-
tion of their agreement with Genzyme
(Sanofi) in early February, exhibited
only a relatively low drop in overall Q1
share price of just 4%. This resilience
suggests a favorable market opinion of
Osiris based on its entire therapeutic
pipeline.
Summary
Publicly traded cell therapy companies
have made a good start to 2012, despite
continued uncertainty in the global stock
markets. The impact of news, both
good and bad, on company share
price is tangible, which suggests that
investors are paying close attention to
the sentiments of this growing industry.
While some share price volatility remains,
increasingly successful fundraising
efforts, including $85M in new capital,
combined with steady clinical trial
progress suggest promising long-term
prospects.ll 10, May 4, 2012 ª2012 Elsevier Inc. 495
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Supplemental Information for this article includes
Table S1 (data and its source) and can be found
with this article online at doi:10.1016/j.stem.2012.
04.018.
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